HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, March 15 (HealthDay News) -- Patients with severe obstructive sleep apnea show more signs of platelet activation and silent brain infarction lesions compared to those with mild or no sleep apnea, researchers report in the March 15 issue of the American Journal of Respiratory and Critical Care Medicine.
Kenji Minoguchi, M.D., Ph.D., of Showa University in Tokyo, Japan, and colleagues measured silent brain infarction by magnetic resonance imaging, and serum levels of soluble CD40 ligand (sCD40L) and soluble P-selectin in 50 male subjects with obstructive sleep apnea. The results were compared with obese control subjects.
Twenty-five percent of patients with severe sleep apnea had silent brain infarctions compared with 7.7 percent for those with mild sleep apnea and 6.7 percent for controls. Serum levels of both sCD40L and sP-selectin were both higher in moderate to severe sleep apnea patients compared to mild apnea and were reduced by nasal continuous positive airway pressure (nCPAP) treatment.
"These results suggest that serum levels of sCD40L and sP-selectin are elevated and silent brain infarction is more common in patients with moderate to severe obstructive sleep apnea, leading to elevated cerebrovascular morbidity," the authors conclude. "Moreover, nCPAP may be useful for decreasing risk in patients with moderate to severe obstructive sleep apnea."
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.